1.30
5.80%
-0.08
After Hours:
1.31
0.01
+0.77%
BioRestorative Therapies Inc stock is currently priced at $1.30, with a 24-hour trading volume of 74,316.
It has seen a -5.80% decreased in the last 24 hours and a -6.47% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.37 pivot point. If it approaches the $1.29 support level, significant changes may occur.
Previous Close:
$1.38
Open:
$1.34
24h Volume:
74,316
Market Cap:
$8.80M
Revenue:
$130.20K
Net Income/Loss:
$-15.94M
P/E Ratio:
-0.2731
EPS:
-4.76
Net Cash Flow:
$-6.55M
1W Performance:
-5.11%
1M Performance:
-6.47%
6M Performance:
-30.11%
1Y Performance:
-74.31%
BioRestorative Therapies Inc Stock (BRTX) Company Profile
Name
BioRestorative Therapies Inc
Sector
Industry
Phone
631 760 8100
Address
40 Marcus Drive, Suite 1, Melville
BioRestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative Therapies (OTCMKTS:BRTX) Share Price Crosses Above Fifty Day Moving Average of $1.35 - Defense World
Defense World
The Globe and Mail - The Globe and Mail
The Globe and Mail
BioRestorative inks deal with Cartessa for aesthetics product - Investing.com India
Investing.com India
BioRestorative inks deal with Cartessa for aesthetics product - Investing.com Australia
Investing.com Australia
BioRestorative inks deal with Cartessa for aesthetics product - Investing.com UK
Investing.com UK
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into ... - AccessWire
AccessWire
BioRestorative Therapies Inc Stock (BRTX) Financials Data
BioRestorative Therapies Inc (BRTX) Revenue 2024
BRTX reported a revenue (TTM) of $130.20 thousand for the quarter ending September 30, 2023, a +7.51% rise year-over-year.
BioRestorative Therapies Inc (BRTX) Net Income 2024
BRTX net income (TTM) was -$15.94 million for the quarter ending September 30, 2023, a +53.87% increase year-over-year.
BioRestorative Therapies Inc (BRTX) Cash Flow 2024
BRTX recorded a free cash flow (TTM) of -$6.55 million for the quarter ending September 30, 2023, a -15.60% decrease year-over-year.
BioRestorative Therapies Inc (BRTX) Earnings per Share 2024
BRTX earnings per share (TTM) was -$4.12 for the quarter ending September 30, 2023, a +57.64% growth year-over-year.
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
Cap:
|
Volume (24h):